{"count": 1, "results": [{"_id": "40931739", "pmid": 40931739, "title": "[Tirzepatide (Mounjaro ) : a GIP/GLP-1 receptor dual agonist for the treatment of type 2 diabetes].", "journal": "Rev Med Liege", "authors": ["Scheen A"], "date": "2025-09-01T00:00:00Z", "meta_date_publication": "2025 Sep", "meta_volume": "80", "meta_issue": "9", "meta_pages": "618-624", "score": 50252.945, "text_hl": "Tirzepatide is now refunded under conditions in Belgium for the treatment of @<m>DISEASE_Thanatophoric_dysplasia_type_2</m> @DISEASE_MESH:C536508 @@@TD2@@@ in @SPECIES_9606 @@@patients@@@ with a body mass index >= 30 kg/m2 and a HbA1c level > 7.5 % with antihyperglycaemic therapy including @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@. ", "citations": {"NLM": "Scheen A. [Tirzepatide (Mounjaro ) : a GIP/GLP-1 receptor dual agonist for the treatment of type 2 diabetes]. Rev Med Liege. 2025 Sep;80(9):618-624. PMID: 40931739", "BibTeX": "@article{40931739, title={[Tirzepatide (Mounjaro ) : a GIP/GLP-1 receptor dual agonist for the treatment of type 2 diabetes].}, author={Scheen A}, journal={Rev Med Liege}, volume={80}, number={9}, pages={618-624}}"}}]}